Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.

Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, Poku EK, Rockne RC, Raubitschek AA, Shively JE, Colcher DM.

J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21. Erratum in: J Nucl Med. 2018 Feb;59(2):346.

2.

Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.

Sta Maria NS, Barnes SR, Weist MR, Colcher D, Raubitschek AA, Jacobs RE.

PLoS One. 2015 Nov 10;10(11):e0142767. doi: 10.1371/journal.pone.0142767. eCollection 2015.

3.

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA.

J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630. Epub 2013 Dec 12.

4.

Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.

Ng TS, Wert D, Sohi H, Procissi D, Colcher D, Raubitschek AA, Jacobs RE.

Clin Cancer Res. 2013 May 1;19(9):2518-27. doi: 10.1158/1078-0432.CCR-12-2738. Epub 2013 Mar 26.

5.

Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner.

Ng TS, Bading JR, Park R, Sohi H, Procissi D, Colcher D, Conti PS, Cherry SR, Raubitschek AA, Jacobs RE.

J Nucl Med. 2012 Jul;53(7):1102-9. doi: 10.2967/jnumed.111.099861. Epub 2012 Jun 1.

6.

Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.

Li L, Crow D, Turatti F, Bading JR, Anderson AL, Poku E, Yazaki PJ, Carmichael J, Leong D, Wheatcroft D, Raubitschek AA, Hudson PJ, Colcher D, Shively JE.

Bioconjug Chem. 2011 Apr 20;22(4):709-16. doi: 10.1021/bc100464e. Epub 2011 Mar 24. Erratum in: Bioconjug Chem. 2011 Jun 15;22(6):1256. Wheatcroft, Michael P [corrected to Wheatcroft, David].

7.

Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.

James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW.

J Immunol. 2010 Apr 15;184(8):4284-94. doi: 10.4049/jimmunol.0903701. Epub 2010 Mar 10. Erratum in: J Immunol. 2010 Jul 15;185(2):1340.

8.

Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity.

Gagnon P, Cheung CW, Lepin EJ, Wu AM, Sherman MA, Raubitschek AA, Yazaki PJ.

Bioprocess Int. 2010 Feb;8(2):26-35.

9.

ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM.

Protein Eng Des Sel. 2010 Apr;23(4):243-9. doi: 10.1093/protein/gzp081. Epub 2010 Jan 6.

10.

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM.

J Nucl Med. 2009 Sep;50(9):1500-8. doi: 10.2967/jnumed.108.060426. Epub 2009 Aug 18.

11.

Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.

Bartlett DW, Colcher D, Raubitschek AA.

Bioconjug Chem. 2008 Sep;19(9):1927-37. doi: 10.1021/bc800223x. Epub 2008 Aug 23.

12.

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW.

J Immunol. 2008 May 15;180(10):7028-38.

13.

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ.

J Clin Oncol. 2008 Jan 1;26(1):90-5. Epub 2007 Nov 19.

PMID:
18025438
14.

Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.

Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE.

J Immunother. 2007 May-Jun;30(4):396-405.

PMID:
17457214
15.

Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.

Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2007 Jan 15;67(2):718-26.

16.

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.

Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA.

Cancer Biother Radiopharm. 2006 Apr;21(2):88-100.

PMID:
16706629
17.

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM.

Cancer Res. 2005 Jul 1;65(13):5907-16.

18.

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2005 Jan 15;65(2):622-31.

19.

Humanization of the anti-CEA T84.66 antibody based on crystal structure data.

Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, Wong JY, Colcher D, Wu AM, Raubitschek AA.

Protein Eng Des Sel. 2004 May;17(5):481-9. Epub 2004 Aug 17.

PMID:
15316127
20.

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.

Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA.

Clin Cancer Res. 2004 Aug 1;10(15):5014-21.

21.

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.

Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF, Wu AM.

Protein Eng Des Sel. 2004 Apr;17(4):315-23. Epub 2004 Jun 8.

PMID:
15187222
22.

Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.

Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, Sherman MA, Williams LE, Shively JE, Raubitschek AA, Wu AM.

Protein Eng Des Sel. 2004 Jan;17(1):21-7.

23.

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.

Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5842-52. Review.

24.

124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM.

J Nucl Med. 2003 Dec;44(12):1962-9.

25.
26.

The two types of correction of absorbed dose estimates for internal emitters.

Williams LE, Liu A, Yamauchi DM, Lopatin G, Raubitschek AA, Wong JY.

Cancer. 2002 Feb 15;94(4 Suppl):1231-4.

27.

Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange.

Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ, Raubitschek AA.

Protein Eng. 2001 Dec;14(12):1025-33.

PMID:
11809933
28.
29.

Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.

Yazaki PJ, Shively L, Clark C, Cheung CW, Le W, Szpikowska B, Shively JE, Raubitschek AA, Wu AM.

J Immunol Methods. 2001 Jul 1;253(1-2):195-208.

PMID:
11384681
30.

Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.

Tsai SW, Li L, Williams LE, Anderson AL, Raubitschek AA, Shively JE.

Bioconjug Chem. 2001 Mar-Apr;12(2):264-70.

PMID:
11312688
31.

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY, Shively JE, Raubitschek AA.

Bioconjug Chem. 2001 Mar-Apr;12(2):220-8.

PMID:
11312683
32.

Numerical selection of optimal tumor imaging agents with application to engineered antibodies.

Williams LE, Wu AM, Yazaki PJ, Liu A, Raubitschek AA, Shively JE, Wong JY.

Cancer Biother Radiopharm. 2001 Feb;16(1):25-35.

PMID:
11279795
33.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 2000 Oct;6(10):3855-63.

34.

High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.

Wu AM, Yazaki PJ, Tsai Sw, Nguyen K, Anderson AL, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JY, Toyokuni T, Phelps ME, Gambhir SS.

Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8495-500.

35.

Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies.

Williams LE, Liu A, Wu AM, Yazaki PJ, Yamauchi DM, Lopatin G, Raubitschek AA, Wong JY.

Med Phys. 2000 May;27(5):988-94.

PMID:
10841401
36.

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE.

Bioconjug Chem. 2000 May-Jun;11(3):327-34.

PMID:
10821648
37.

Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.

Wong JY, Wang J, Liu A, Odom-Maryon T, Shively JE, Raubitschek AA, Williams LE.

Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):599-607.

PMID:
10701739
38.

A method for patient-specific absorbed dose estimation for internal beta emitters.

Williams LE, Liu A, Raubitschek AA, Wong JY.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3015s-3019s.

PMID:
10541337
39.

Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.

Wong JY, Somlo G, Odom-Maryon T, Williams LE, Liu A, Yamauchi D, Wu AM, Yazaki P, Wilczynski S, Shively JE, Forman S, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3224s-3231s.

PMID:
10541368
40.

A radionuclide therapy treatment planning and dose estimation system.

Liu A, Williams LE, Lopatin G, Yamauchi DM, Wong JY, Raubitschek AA.

J Nucl Med. 1999 Jul;40(7):1151-3.

41.

Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy.

Clarke KG, Odom-Maryon TL, Williams LE, Liu A, Lopatin G, Chou J, Farino GM, Raubitschek AA, Wong JY.

Med Phys. 1999 May;26(5):799-809.

PMID:
10360545
42.

Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.

Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.

J Nucl Med. 1998 Dec;39(12):2097-104.

43.

Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry.

Liu A, Williams LE, Wong JY, Raubitschek AA.

Nucl Med Biol. 1998 May;25(4):423-33. Review.

PMID:
9639305
45.

Estimating residence times and their associated errors in patient absorbed-dose calculation.

Kaplan DD, Williams LE, Clarke KG, Odom-Maryon TL, Liu A, Lopatin G, Raubitschek AA, Wong JY.

J Nucl Med Technol. 1997 Dec;25(4):264-8.

PMID:
9438927
46.

Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.

Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, Chou J, Clarke KG, Raubitschek AA.

J Nucl Med. 1997 Dec;38(12):1959-66.

47.

Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.

Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.

J Nucl Med. 1997 Dec;38(12):1951-9.

48.

A CT assisted method for absolute quantitation of internal radioactivity.

Liu A, Williams LE, Raubitschek AA.

Med Phys. 1996 Nov;23(11):1919-28.

PMID:
8947907
49.

Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies.

Williams LE, Liu A, Wu AM, Odom-Maryon T, Chai A, Raubitschek AA, Wong JY.

Med Phys. 1995 Dec;22(12):2025-7. No abstract available.

PMID:
8746707
50.

On the correction for radioactive decay in pharmacokinetic modeling.

Williams LE, Odom-Maryon TL, Liu A, Chai A, Raubitschek AA, Wong JY, D'Argenio DZ.

Med Phys. 1995 Oct;22(10):1619-26.

PMID:
8551986

Supplemental Content

Loading ...
Support Center